

---

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

FORM 8-K

Current Report  
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (date of earliest event reported): February 16, 2015

**LION BIOTECHNOLOGIES, INC.**  
(Exact Name of Registrant as Specified in Charter)

**Nevada**

(State or other jurisdiction of  
incorporation or organization)

**75-3254381**

(I.R.S. employer  
identification number)

**21900 Burbank Blvd, Third Floor, Woodland Hills, CA 91367**

(Address of principal executive offices and zip code)

**(818) 992-3126**

(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425).
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12).
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)).
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)).
-

**Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**

On February 16, 2015, the Board of Directors of Lion Biotechnologies, Inc. (the “Company”) appointed Ryan D. Maynard as a new member of the Board and as the Chair of the Company’s Audit Committee. Mr. Maynard will serve as a director on the Board until the Company’s 2015 Annual Meeting of Stockholders and until his successor has been duly elected and qualified, or until his earlier death, resignation or removal.

Mr. Maynard currently is the Executive Vice President and Chief Financial Officer of Rigel Pharmaceuticals, Inc., a clinical-stage drug development public company. He joined Rigel in September 2001 as Corporate Controller and was appointed as an Assistant Secretary in October 2001. In June 2006 he became Vice President of Finance and Acting Chief Financial Officer and became our Vice President and Chief Financial Officer in January 2007. Prior to joining Rigel, Mr. Maynard was Corporate Controller and Director of Finance and Accounting for Personify, Inc., an e-commerce software company, from November 1999 to April 2001. From July 1998 to October 1999 he served as Controller of General Magic, Inc. and from July 1994 to June 1998 he held various positions at Siliconix, Inc., most recently as Senior Finance Manager. He previously worked at Ernst & Young, LLP, where he became a certified public accountant. Mr. Maynard holds a B.S. in Commerce—Accounting from Santa Clara University.

There are no arrangements or understandings between Mr. Maynard and any other persons pursuant to which he was elected as a director of the Company. There are no family relationships between Mr. Maynard and any director, executive officer, or any person nominated or chosen by the Company to become a director or executive officer. Mr. Maynard is not a party to any current or proposed transaction with the Company for which disclosure is required under Item 404(a) of Regulation S-K.

A copy of the press release announcing Mr. Maynard’s election to the Board is attached as Exhibit 99.1 to this current report on Form 8-K and is incorporated by reference herein.

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.

**LION BIOTECHNOLOGIES, INC.**

Date: February 18, 2015

By: /s/ Michael Handelman

Michael Handelman, Chief Financial Officer



## **Lion Biotechnologies Appoints Ryan Maynard Director and Chair of Audit Committee**

**LOS ANGELES, CA** (February 17, 2015) – Lion Biotechnologies, Inc. (LBIO), a biotechnology company that is developing novel cancer immunotherapies based on tumor-infiltrating lymphocytes (TIL), today announced that its board of directors has appointed Ryan Maynard to serve as a director and chair of the audit committee. His appointment is effective immediately.

Since 2010, Mr. Maynard has served as executive vice president and chief financial officer of Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL), where he previously held several senior financial positions since 2001. Prior to joining Rigel, Mr. Maynard served as corporate controller and director of finance and accounting for Personify, Inc., and controller of General Magic, Inc. He has also held various positions at Siliconix, Inc., most recently as senior finance manager. Earlier in his career, Mr. Maynard worked at Ernst & Young, LLP, where he became a certified public accountant. He holds a B.S. in accounting from Santa Clara University.

“We are delighted to welcome Ryan to Lion’s board as a director and audit committee chairman,” said Elma Hawkins, President & CEO. “Ryan has a wealth of experience in corporate financial management and reporting, as well as an impressive track record in fundraising for public companies. We are confident that his insights and expertise will prove a valuable asset to the company.”

### **About Lion Biotechnologies**

Lion Biotechnologies, Inc. is engaged in the development of T cells and engineered T cells for the treatment of various cancers. The company’s lead product candidate, LN-144, is a ready-to-infuse, autologous T-cell therapy utilizing tumor-infiltrating lymphocytes (TIL) for the treatment of patients with metastatic melanoma, and is based on a clinical Cooperative Research and Development Agreement with the National Cancer Institute. TIL therapy is also being evaluated in physician-sponsored clinical trials at MD Anderson Cancer Center and the H. Lee Moffitt Cancer Center & Research Institute. For more information, please visit <http://www.lionbio.com>.

### **Investor Relations**

The Trout Group  
Tricia Truehart  
646-378-2953  
[ttruehart@troutgroup.com](mailto:ttruehart@troutgroup.com)